Navigation Links
Spherix Announces Third Quarter 2010 Financial Results
Date:11/15/2010

Society of North America, July 10-14, 2010, St. Petersburg Beach, FL
  • Attended 2010 IFT Annual Meeting & Food Expo, July 12-20, 2010, Chicago, IL
  • November 1-3, 2010, Invited by the NIOH of South Africa to present a series of lectures dealing with Risk Assessment and Food Safety in Johannesburg, South Africa
  • Presented "Food Ingredient Approvals:  The Science and Regulatory Process for GRAS Determinations in the US and Novel Foods in Europe" at the Health Ingredients Japan 2010 Conference in Tokyo
  • Presented "Stevia...The Science Behind the Sweetness" at the Supply Side West post-conference Stevia: Trends, Product Development and Regulatory Update Workshop in Las Vegas, October 23, 2010
  • December 8, 2010: Invited to present "Probiotics: Advances in the Assessment of Safe Use" during Virgo Publishing's Probiotics Webinar

    • Financial Results for the Quarter Ended September 30, 2010Revenue and direct costs are directly related to the Company's health sciences consulting segment.  The Company's consulting business provides technical and regulatory consulting services to biotechnology and pharmaceutical companies, as well as critical technical support for the Company's own R&D activities.

    The Company's ongoing research and development activities have been focused on the development of D-tagatose as a new treatment for Type 2 diabetes.  The Company announced in June that it would also explore D-Tagatose as a potential treatment for high triglycerides, a risk factor for atherosclerosis, myocardial infraction, and stroke. The R&D expenditures for 2010 and 2009 consisted of both a Phase 3 clinical trial and a related Phase 2 Dose Range study on the use of D-tagatose as a treatment for Type 2 diabetes.

    D-Tagatose is believed to depress elevations of blood sugar levels in diabetic patients by increasing glycogen synthesis while decreasing glycogen utilization, resulting in an im
    '/>"/>

    SOURCE Spherix Incorporated
    Copyright©2010 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Spherix Awarded Grant from U.S. Government Under the Patient Protection and Affordable Care Act
    2. Spherix Announces Institutional Investors Purchase $5.25 Million of Convertible Preferred Stock and Warrants
    3. Spherix Completes Enrollment in NEET, a Phase 3 Clinical Trial Evaluating an Oral Drug for Type 2 Diabetes
    4. Spherix to Present at Annual OneMedPlace Finance Forum and at EBD Biotech Showcase in San Francisco
    5. Spherix Reports Third Quarter 2009 Earnings
    6. Spherix Announces Positive Phase 2 Study Results
    7. Spherix Reports First Quarter 2009 Earnings
    8. Spherix Elects New Independent Director, and Elects Chairman of the Board
    9. Spherix Postpones 2009 Annual Shareholders Meeting to Share Interim Diabetes Clinical Trial Data
    10. Spherix Expands Phase 3 Naturlose Diabetes Trial Outside of the U.S.
    11. Spherix D-tagatose to be Supplied by Inalco SpA
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/23/2013)... Conn. , May 23, 2013  CAS Medical Systems, ... medical devices for non-invasive patient monitoring, today announced that ... Officer,  will present at the 2 nd Annual Marcum ... Hyatt Hotel in New York City . ... p.m. ET in the Estate 10 room and will be ...
    (Date:5/23/2013)... 2013 EarlySense, the market leader ... prize for ,Best Novel Idea, at the 8 th ... International Conference, hosted this year in the UK by ... clinical research team studying the impact of the EarlySense ... Los Angeles . The prize was awarded ...
    (Date:5/23/2013)... 2013  Inhibikase Therapeutics, Inc., an emerging leader ... will present new results on its antiviral program ... by the PML Consortium (composed of Pfizer, Bristol-Meyers ... is the causative agent of Progressive Multifocal Leukoencephalopathy ... an extended release formulation, can clear JC polyomavirus ...
    Breaking Medicine Technology:CASMED to Present at the 2nd Annual Marcum MicroCap Conference 2Clinical Team Researching the Impact of the EarlySense System Wins 'Best Novel Idea' Prize at the Rapid Response Systems and Medical Emergency Teams 2013 8th International Conference 2Clinical Team Researching the Impact of the EarlySense System Wins 'Best Novel Idea' Prize at the Rapid Response Systems and Medical Emergency Teams 2013 8th International Conference 3Clinical Team Researching the Impact of the EarlySense System Wins 'Best Novel Idea' Prize at the Rapid Response Systems and Medical Emergency Teams 2013 8th International Conference 4Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML) 2
    ... Dual EGFR / HER2 Tyrosine Kinase Inhibitor, Suggests Activity ... Mutations - (1,2)-The First Presentation of Data on BIBF ... Ingelheim will present new data on the company,s two ... the 2009 Annual Meeting of the American Society of ...
    ... TYRX, Inc., a leader in the ... the 30th Annual Scientific Sessions of the Heart ... its AIGISRX(TM) Antibacterial Envelope Retrospective Registry.AIGIS is an ... that help provide protection against infections associated with ...
    Cached Medicine Technology:Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 2Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 3Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 4Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 5Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 6Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 7Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 8Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 9Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 10TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry 2TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry 3TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry 4TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry 5TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry 6
    (Date:5/23/2013)... The Rottenstein Law Group LLP, a New York-based nationwide ... Information Center at http://www.rotlaw.com/tylenol , dedicated to issues ... considering filing lawsuits. , The painkiller Tylenol (acetaminophen) ... according to a 2009 report from the U.S. Food ... FDA warned consumers against using more than the recommended ...
    (Date:5/23/2013)... Washington, DC (PRWEB) May 23, 2013 ... have a great deal of control over their level ... their weight, yet far fewer are actually taking that ... International Food Information Council (IFIC) Foundation’s 2013 Food & ... of respondents say it’s possible to have “a great ...
    (Date:5/23/2013)... IL (PRWEB) May 23, 2013 Jeanne ... fifth anniversary of its popular and only free OCD ... a successful continuing resource for OCD sufferers, the group ... OCD, and related disorders. This allows group participants ... and Exposure and Response Prevention. , “Participants in Beyond ...
    (Date:5/23/2013)... May 23 (HealthDay News) -- Schools should ensure ... physical activity each day to support their health ... new report. Although previous studies show ... promotes health and development, it,s estimated that only ... meeting this recommendation, according to the report from ...
    (Date:5/23/2013)... Reporter , , THURSDAY, May 23 (HealthDay News) -- Heavy ... as methamphetamine or crack cocaine, a new study contends. ... or ,coke mouth, it is startling to see the ... same," said Dr. Mohamed Bassiouny, a professor of restorative ... Philadelphia. Methamphetamine, crack cocaine and soda -- sweetened ...
    Breaking Medicine News(10 mins):Health News:Rottenstein Law Group LLP Now Accepting Tylenol Cases, Announces New Tylenol Lawsuit Information Center 2Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 2Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 3Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 4Health News:Beyond OCD Support Group Marks Fifth Anniversary 2Health News:U.S. School Kids Should Get Hour of Exercise Daily: Report 2Health News:Diet Soda Habit as Bad for Teeth as Meth Addiction, Study Claims 2Health News:Diet Soda Habit as Bad for Teeth as Meth Addiction, Study Claims 3
    ... SHANGHAI, Sept. 10 /PRNewswire-Asia/ -- ... announced that Dr. Ge Li, the Company,s Chairman and ... Healthcare,Unplugged Conference in New York on Tuesday, September 15, ... present at the Bank of America Merrill,Lynch Global Healthcare ...
    ... 9 Family Research Council President Tony Perkins made the ... joint session of Congress. , , ... Tomorrow night in a live webcast at frcaction.org, ... Perkins will be joined by Senator Jim DeMint (R-SC), House ...
    ... , , MANASSAS, Va., Sept. 9 , ... of ConservativeHQ.com, regarding President Obama,s speech on health care legislation: ... far-left agenda by re-launching an effort for government-run health care. ... Obama is re-launching the conservative movement. , , ...
    ... , , , ... no meaningful health care reform , , ... Congress Wednesday evening, USAction President William McNary called on Congress to ... companies - and pass quality, affordable health care reform with a ...
    ... , OAKLAND, Calif., Sept. 9 ... "Technologies for Home and Community-Based Services: Considering the Options," at ... the City Center Marriott Hotel in Oakland on Friday, September 11, ... Lindeman, Ph.D.; Lynn Redington, Dr.PH., M.B.A.; and Valerie Steinmetz. They will ...
    ... action of nitrogen-containing bisphosphonate (N-BP) cancer drugs, used to ... bone metastasis, has been almost entirely unknown. Researchers writing ... have used ,barcoded, yeast mutants to identify new ... opening up opportunities for the development of new anticancer ...
    Cached Medicine News:Health News:WuXi PharmaTech to Participate in Upcoming Investor Conferences 2Health News:President Obama's Campaign Style Speech Points to a Health Care Plan on Life Support 2Health News:Richard Viguerie: Obamacare is Restarting the Conservative Movement 2Health News:Technologies That Redefine Care for Older Americans to be Focus of Conference Session Led by Center for Technology and Aging 2
    ... The G-4 goniolaser lens features 4 precisely ... 360° view of the anterior chamber angle ... design (flanged glass contact element) provides a ... segment. 4 mirror lens provides ...
    The Mid Field 30° lens has a bi-concave design to provide a wider field of view with a 30 degree offset image....
    ... The Chalam 45° Prism ... pathologies and are recommended for ... etc.) and Rhegmatogenus retinal detachment. ... panretinal photocoagulation and other midperipheral ...
    ... High-Mag 1.5x is specifically designed ... in macular hole surgery, optic ... membrane removal, traditional macular edema ... magnification. This lens was developed ...
    Medicine Products: